Published Date: Feb-19
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Asia Pacific Smart Insulin Pen Market, published by KBV research, the Asia Pacific Smart Insulin Pen Market would witness market growth of 11.4% CAGR during the forecast period (2018 – 2024).
The Japan market would dominate the Asia Pacific Prefilled Market by 2024, growing at a CAGR of 9.9 % during the forecast period. The China market is expected to witness a CAGR of 10.2% during (2018 - 2024). Additionally, The India market is expected to witness a CAGR of 12.7% during (2018 - 2024).
The Hospitals & Clinics market dominated the Asia Pacific Smart Insulin Pen Market by End User in 2017. The Ambulatory Surgical Centers market is expected to witness a CAGR of 11.9% during (2018 - 2024).
The First Generation Pens market dominated the Malaysia Smart Insulin Pen Market by Product in 2017, and would achieve a market value of $701.9 Thousand by 2024. The Second Generation Pens market is expected to witness a CAGR of 13.1% during (2018 - 2024).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Companion Medical Inc., Digital Medics Ptd Ltd., Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Emperra GmbH E-Health Technologies, Jiangsu Delfu medical device Co. Ltd., Bigfoot biomedica.
Asia Pacific Smart Insulin Pen Market Segmentation
By End User
Unique Offerings from KBV Research